Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

BACKGROUND: The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed based on the results of immunogenicity studies and correlates of protection derived from randomized clinical trials of the 7-valent conjugate pneumococcal vaccine. We assessed the vaccination effectiveness (VE) of the PCV1...

Descripción completa

Detalles Bibliográficos
Autores principales: Domínguez, Ángela, Ciruela, Pilar, Hernández, Sergi, García-García, Juan José, Soldevila, Núria, Izquierdo, Conchita, Moraga-Llop, Fernando, Díaz, Alvaro, F. de Sevilla, Mariona, González-Peris, Sebastià, Campins, Magda, Uriona, Sonia, Martínez-Osorio, Johanna, Solé-Ribalta, Anna, Codina, Gemma, Esteva, Cristina, Planes, Ana María, Muñoz-Almagro, Carmen, Salleras, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555701/
https://www.ncbi.nlm.nih.gov/pubmed/28806737
http://dx.doi.org/10.1371/journal.pone.0183191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555701/
https://www.ncbi.nlm.nih.gov/pubmed/28806737
http://dx.doi.org/10.1371/journal.pone.0183191

Ejemplares similares